Literature DB >> 29733427

Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer.

Heba M Hesham1, Deena S Lasheen1, Khaled A M Abouzid1.   

Abstract

Recently, molecular hybridization paradigm became an interesting and smart way to defeat the multifaceted cancer disease by a single molecular entity that acts via several mechanisms just like a magic bullet. Also, HDAC is an important epigenetic target in drug discovery, and the HDAC inhibitors showed successful pattern as cytotoxic agents. Because of their flexible structure activity relationship, it was easy to link them to other anticancer scaffolds. So, many dual action HDAC inhibitors have been developed and most of these hybrids have higher potency than the constituting parents in fighting of the cancer cells. This review describes potential applications of chimeric HDAC inhibitors, which simultaneously modulate not only HDAC but also multiple targets, in treatment of relapsing and drug-resistant cancers. We have nearly collected most of the reported dual action HDAC inhibitors yet to provide a comprehensive guide for the drug discovery process for developing more efficient anticancer agents.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  cancer resistance; cancer stem cell; chimeric anticancer agents; dual action HDAC inhibitors; molecular hybridization

Mesh:

Substances:

Year:  2018        PMID: 29733427     DOI: 10.1002/med.21505

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  25 in total

1.  Development of a Novel Histone Deacetylase-Targeted Near-Infrared Probe for Hepatocellular Carcinoma Imaging and Fluorescence Image-Guided Surgery.

Authors:  Chu Tang; Yang Du; Qian Liang; Zhen Cheng; Jie Tian
Journal:  Mol Imaging Biol       Date:  2020-06       Impact factor: 3.488

2.  New Dual CK2/HDAC1 Inhibitors with Nanomolar Inhibitory Activity against Both Enzymes.

Authors:  Loganathan Rangasamy; Irene Ortín; José María Zapico; Claire Coderch; Ana Ramos; Beatriz de Pascual-Teresa
Journal:  ACS Med Chem Lett       Date:  2020-04-07       Impact factor: 4.345

3.  Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells.

Authors:  Annalisa Romanelli; Giulia Stazi; Rossella Fioravanti; Clemens Zwergel; Elisabetta Di Bello; Silvia Pomella; Clara Perrone; Cecilia Battistelli; Raffaele Strippoli; Marco Tripodi; Donatella Del Bufalo; Rossella Rota; Daniela Trisciuoglio; Antonello Mai; Sergio Valente
Journal:  ACS Med Chem Lett       Date:  2020-03-19       Impact factor: 4.345

4.  Evidence that HDAC7 acts as an epigenetic "reader" of AR acetylation through NCoR-HDAC3 dissociation.

Authors:  Yuchen Zhang; Rafael Andrade; Anthony A Hanna; Mary Kay H Pflum
Journal:  Cell Chem Biol       Date:  2022-06-15       Impact factor: 9.039

5.  HDAC6 regulates primordial follicle activation through mTOR signaling pathway.

Authors:  Tuo Zhang; Meina He; Lihua Zhao; Shaogang Qin; Zijian Zhu; Xinhua Du; Bo Zhou; Yi Yang; Xinfeng Liu; Guoliang Xia; Tengxiang Chen; Yuanxi Wang; Hua Zhang; Chao Wang
Journal:  Cell Death Dis       Date:  2021-05-29       Impact factor: 8.469

Review 6.  Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy.

Authors:  Mengjiao Zhou; Minjian Yuan; Meng Zhang; Chenyi Lei; Omer Aras; Xiaohong Zhang; Feifei An
Journal:  Eur J Med Chem       Date:  2021-09-04       Impact factor: 7.088

7.  Differential profiles of HDAC1 substrates and associated proteins in breast cancer cells revealed by trapping.

Authors:  Yuchen Zhang; Dhanusha A Nalawansha; Kavinda E Herath; Rafael Andrade; Mary Kay H Pflum
Journal:  Mol Omics       Date:  2021-08-09

8.  A Comparative Study of Target Engagement Assays for HDAC1 Inhibitor Profiling.

Authors:  Rosita R Asawa; Alexey Zakharov; Taylor Niehoff; Ata Chitsaz; Ajit Jadhav; Mark J Henderson; Anton Simeonov; Natalia J Martinez
Journal:  SLAS Discov       Date:  2019-10-29       Impact factor: 3.341

9.  A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.

Authors:  Muhamad Mustafa; Amer Ali Abd El-Hafeez; Dalia Abdelhamid; Gajanan D Katkar; Yaser A Mostafa; Pradipta Ghosh; Alaa M Hayallah; Gamal El-Din A Abuo-Rahma
Journal:  Eur J Med Chem       Date:  2021-05-29       Impact factor: 7.088

10.  Exploring novel capping framework: high substituent pyridine-hydroxamic acid derivatives as potential antiproliferative agents.

Authors:  Fernando Hernández-Borja; Itzel Mercado-Sánchez; Yolanda Alcaraz; Marco A García-Revilla; Clarisa Villegas Gómez; David Ordaz-Rosado; Nancy Santos-Martínez; Rocío García-Becerra; Miguel A Vazquez
Journal:  Daru       Date:  2021-07-23       Impact factor: 4.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.